Related Experiment Video
Updated: Nov 25, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance
Susana Machado1,2, Andreia Silva1,2, Ana Luísa De Sousa-Coelho1,2
1Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal.
Abstract:
Therapy resistance is responsible for most relapses in patients with cancer and is the major challenge to improving the clinical outcome. The pseudokinase Tribbles homologue 2 (TRIB2) has been characterized as an important driver of resistance to several anti-cancer drugs, including the dual ATP-competitive PI3K and mTOR inhibitor dactolisib (BEZ235). TRIB2 promotes AKT activity, leading to the inactivation of FOXO transcription factors, which are known to mediate the cell response to antitumor drugs. To characterize the downstream events of TRIB2 activity, we analyzed the gene expression profiles of isogenic cell lines with different TRIB2 statuses by RNA sequencing. Using a connectivity map-based computational approach, we identified drug-induced gene-expression profiles that invert the TRIB2-associated expression profile. In particular, the natural alkaloids harmine and piperlongumine not only produced inverse gene expression profiles but also synergistically increased BEZ235-induced cell toxicity. Importantly, both agents promote FOXO nuclear translocation without interfering with the nuclear export machinery and induce the transcription of FOXO target genes. Our results highlight the great potential of this approach for drug repurposing and suggest that harmine and piperlongumine or similar compounds might be useful in the clinic to overcome TRIB2-mediated therapy resistance in cancer patients.
Insights
Therapy resistance in cancer is a major challenge. This study found that harmine and piperlongumine can overcome resistance mediated by Tribbles homologue 2 (TRIB2) by reactivating FOXO transcription factors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Therapy resistance causes most cancer relapses and hinders clinical outcomes.
- Tribbles homologue 2 (TRIB2) drives resistance to anti-cancer drugs like dactolisib (BEZ235) by promoting AKT activity and inactivating FOXO transcription factors.
Purpose of the Study:
- To investigate downstream events of TRIB2 activity.
- To identify compounds that can reverse TRIB2-mediated drug resistance.
Main Methods:
- RNA sequencing of isogenic cell lines with varying TRIB2 expression.
- Connectivity map-based computational analysis to identify drugs reversing TRIB2 expression profiles.
- Assessing FOXO transcription factor activity and drug synergy.
Main Results:
- Harmine and piperlongumine reversed TRIB2-associated gene expression profiles.
- These natural alkaloids synergistically enhanced BEZ235-induced cancer cell toxicity.
- Harmine and piperlongumine promoted FOXO nuclear translocation and target gene transcription.
Conclusions:
- The identified computational approach shows potential for drug repurposing.
- Harmine and piperlongumine may be clinically useful for overcoming TRIB2-mediated therapy resistance in cancer patients.
Related Concept Videos
Treatment Resistant Cancers
Drug Biotransformation: Overview
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Phase II Reactions: Miscellaneous Conjugation Reactions
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
Drug Metabolism: Phase II Reactions

